COOPER COMPANIES, INC. 2Q 2026: Revenue $1.08B, Net income ($77.9M), EPS ($0.4) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Cooper Companies reported Q2 2026 revenue of $1.08B, up 7.9% YoY, driven by CooperVision and CooperSurgical. However, the company posted a net loss of ($77.9M) and diluted EPS of ($0.4), compared to prior year profits. The loss was significantly impacted by a $271.6M litigation accrual at CooperSurgical. Despite the net loss, operating cash flow improved, supporting capital spending and share repurchases.
Cooper Companies, Inc. reported second-quarter 2026 results with consolidated revenue of $1.08B, up 7.9% from $1B a year earlier, while the company recorded a net loss of ($77.9M) versus net income of $87.7M in the prior-year quarter; diluted EPS was ($0.4) compared with $0.44 a year ago.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $1.08B | $1B | 7.9% |
| Net income² | ($77.9M) | $87.7M | (188.8%) |
| Diluted EPS³ | ($0.4) | $0.44 | (190.9%) |
¹ Reported as “Net sales”. ² Reported as “Net income (loss)”. ³ Reported as “Earnings (loss) per share”.
Business Highlights
- Revenue growth of about 8% was driven by CooperVision (strong spherical and toric contact lens demand) and CooperSurgical (fertility services).
- Geographic strength in the Americas and EMEA offset softness in Asia Pacific, notably Japan, which weighed on regional mix.
- Brand momentum from Biofinity, MyDay and MiSight— including FDA‑approved MiSight 1 day—supported contact lens and myopia-management adoption.
- CooperSurgical recorded a $271.6M net litigation accrual during the quarter, materially affecting operating results and defense costs.
- Operating cash flow improved, supporting higher capital spending and continued share repurchases while funding operational needs.
Original SEC Filing: COOPER COMPANIES, INC. [ COO ] - 10-Q - Jun. 05, 2026